EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Congenital amegakaryocytic thrombocytopenia with and without clonal evolution to myelodysplastic syndrome: peripheral blood stem cell transplantation outcomes in a pediatric single-center case series

Mina Mokaram Doost Delkhah, Amirali Kalantari, Zahra Karimizadeh, Mohammad Jahanpanah, Arghavan Tajalli, Soudeh Ramezani Natanzi, Leila Jafari, Maryam Behfar, Amir Ali Hamidieh

Annals of Hematology · 16.11.2026

DOI: 10.1007/s00277-026-07368-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 16.11.2026. Verfasst von Mina Mokaram Doost Delkhah und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only cure for congenital amegakaryocytic thrombocytopenia (CAMT). However, transplant outcomes for patients progressing to myelodysplastic syndrome (MDS) with monosomy 7 remain largely unreported.

Methods

We retrospectively analyzed five pediatric CAMT patients undergoing peripheral blood stem cell (PBSC) transplantation. All received uniform non-TBI myeloablative conditioning (busulfan, cyclophosphamide, rATG) with cyclosporine/methotrexate GVHD prophylaxis. Two had progressed to MDS with monosomy 7.

Results

All five patients achieved rapid engraftment (median neutrophil 12 days, platelet 14 days) with donor chimerism > 99% at the last assessment and no primary graft failure. At a 3-year median follow-up, 80% (4/5) remain alive with sustained transfusion independence. The single mortality occurred in a patient with MDS with monosomy 7, who succumbed to grade IV hemorrhagic cystitis, in the setting of grade IV acute GVHD, at two months.

Conclusion

In this small series, non-TBI myeloablative PBSC transplantation was associated with rapid engraftment and durable hematopoietic reconstitution in CAMT without MDS. In patients with pre-existing MDS/monosomy 7, outcomes were heterogeneous (one survivor, one death); given the small sample and concurrent risk factors, an independent effect of MDS/monosomy 7 cannot be established. These observations underscore the importance of early genetic diagnosis and timely HSCT referral.

Zitieren

APA

Delkhah, M. M. D., Kalantari, A., Karimizadeh, Z., Jahanpanah, M., Tajalli, A., Natanzi, S. R., Jafari, L., Behfar, M., & Hamidieh, A. A. (2026). Congenital amegakaryocytic thrombocytopenia with and without clonal evolution to myelodysplastic syndrome: peripheral blood stem cell transplantation outcomes in a pediatric single-center case series. Annals of Hematology. https://doi.org/10.1007/s00277-026-07368-4

Vancouver

Delkhah MMD, Kalantari A, Karimizadeh Z, Jahanpanah M, Tajalli A, Natanzi SR, et al. Congenital amegakaryocytic thrombocytopenia with and without clonal evolution to myelodysplastic syndrome: peripheral blood stem cell transplantation outcomes in a pediatric single-center case series. Annals of Hematology. 2026. doi:10.1007/s00277-026-07368-4

BibTeX
@article{Delkhah2026,
  author = {Delkhah, Mina Mokaram Doost and Kalantari, Amirali and Karimizadeh, Zahra and Jahanpanah, Mohammad and Tajalli, Arghavan and Natanzi, Soudeh Ramezani and Jafari, Leila and Behfar, Maryam and Hamidieh, Amir Ali},
  title = {Congenital amegakaryocytic thrombocytopenia with and without clonal evolution to myelodysplastic syndrome: peripheral blood stem cell transplantation outcomes in a pediatric single-center case series},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07368-4}
}
Kostenlos starten →